Guide for Authors
Gynecologic
Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of
the female reproductive tract. We welcome the submission of investigations relating to the etiology, diagnosis, treatment, and prevention
of female cancers, as well as research from any of the disciplines related to this field of interest. Research areas include: cell and
molecular biology, chemotherapy, clinical trails, epidemiology, genetics, immunology and vaccines, 'omics', pathology and cytology, quality
of life, radiation therapy, surgery, and translational research. All aspects of scholarship related to tumors of this region are welcome,
with originality, quality, and clarity the chief criteria of acceptance.
Types of Articles
Original
Research Report: Full-length report of an original basic or clinical investigation.
Review Article: A comprehensive
and scholarly review of the literature relating to an important basic or clinical subject, accompanied by critical analysis and leading
to reasonable conclusions.
Letter to the Editor: May consist of either of two types of correspondence: (1) a question or
challenge to article published recently in the journal or (2) a brief communication describing a preliminary research report or a review.
Editorial: Commentary on an original article published in the same issue or an opinion or perspective on a specific topic.
Clinical Commentary: Offers perspective or opinion of clinical relevance.
Surgical Films: Gynecologic Oncology
has begun accepting video submissions. Authors who have video or animation files that they wish to submit are strongly encouraged to
adhere to the guidelines detailed below. All submitted files should be properly labeled so that they directly relate to the video file's
content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended
file formats with a preferred maximum size of 100 MB. Video and animation files supplied will be published online in the electronic version
of your article in Elsevier Web products, including ScienceDirect:
http://www.sciencedirect.com. Please supply 'stills'
with your file: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard
icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at
http://www.elsevier.com/artworkinstructions.
Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and
the print version for the portions of the article that refer to this content.
Ethics in publishing
For information on Ethics in publishing and Ethical guidelines for journal publication
see
http://www.elsevier.com/publishingethics and
http://www.elsevier.com/ethicalguidelines.
Clinical Trial Guidelines
We invite submission of all clinical trials, whether phase I, II, or III. For phase
I trials, we especially encourage those of a novel substance for a novel indication, if there is a strong or unexpected beneficial or
adverse response, or a novel mechanism of action. Systematic reviews of randomised trials also might warrant rapid peer review and publication.
We encourage the registration of all interventional trials, whether early or late phase, in a primary register that participates in WHO's
International Clinical Trial Registry Platform. We also encourage full public disclosure of the minimum 20-item trial registration dataset
at the time of registration and before recruitment of the first participant (
http://www.who.int/ictrp/en/). The registry
must be independent of for-profit interest. Reports of randomised trials must conform to revised CONSORT guidelines, and should be submitted
with their protocols. All reports of clinical trials must include a summary of previous research findings, and explain how this trial
contributes to the sum of knowledge. The relation between existing and new evidence should be shown by direct reference to an existing
systematic review and meta-analysis; if neither exists, authors are encouraged to do their own, or to describe the qualitative association
between their research and previous findings.
• Cluster randomised trials must be reported according to CONSORT extended guidelines.
• Randomised trials that report harms must be described according to extended to extended CONSORT guidelines.
• Studies
of diagnostic accuracy must be reported according to STARD guidelines.
• Systematic reviews must be written according to the
Cochrane Collaboration guidelines.
• Observational studies (cohort, case-control, or cross-sectional designs) must be reported
according to the STROBE statement.
Conflict of Interest
All authors are requested to disclose
any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations
within 24 months of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See
also
http://www.elsevier.com/conflictsofinterest.
Gynecologic Oncology requires full disclosure of all potential
conflicts of interest. All authors must complete and sign the official
Gynecologic Oncology conflict of interest form, which
may be found
here.
Each and every author must disclose any potential conflict of interest as defined on the form itself.
The conflict of interest form
may be submitted in several ways: 1) download the form, have all authors place an official digital signature on the form, and upload
it to your submission; 2) download the form, print it out, hand sign it, scan the signed form, and upload the scanned file to your submission;
or 3) download the form, hand sign it, and fax all signed forms together to +1 (619) 699-6700. Please ensure that if you fax the forms,
you gather all forms and fax them together
before approving your submission.
You will receive confirmation of receipt for
all conflict of interest forms. If signed conflict of interest forms are not provided upon submission, your submission will be returned
to you with a request that you provide signed forms for all authors. Your manuscript will not be considered for publication by editors
or reviewers until all signed conflict of interest forms have been received.
Role of Medical Writer or
Editor
If a medical writer or editor was involved in the creation of your manuscript, we need a signed statement from the
corresponding author to include their name and information about funding of this person. This information should be added to the Acknowledgement
section. We also require signed statements from any medical writers or editors declaring that they have given permission to be names
as an author; or in the Acknowledgments section.
Submission declaration and verification
Submission
of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published
lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors
and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published
elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder.
To verify originality, your article may be checked by the originality detection software iThenticate. See also
http://www.elsevier.com/editors/plagdetect.
Changes to authorship
This policy concerns the addition, deletion, or rearrangement of author names in the
authorship of accepted manuscripts:
Before the accepted manuscript is published in an online issue: Requests to add or remove
an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript
and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail,
fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors,
this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded
by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers
will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until
authorship has been agreed.
After the accepted manuscript is published in an online issue: Any requests to add, delete, or
rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.
Copyright
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement'
(for more information on this and copyright see
http://www.elsevier.com/copyright). Acceptance of the agreement will ensure
the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript
together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Subscribers may reproduce
tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of
the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations
and translations (please consult
http://www.elsevier.com/permissions). If excerpts from other copyrighted works are included,
the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted
forms for use by authors in these cases: please consult
http://www.elsevier.com/permissions.
Retained
author rights
As an author you (or your employer or institution) retain certain rights; for details you are referred to:
http://www.elsevier.com/authorsrights.
Role of the Funding Source
As an author
you (or your employer or institution) retain certain rights; for details you are referred to:
http://www.elsevier.com/authorsrights
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and
to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the
writing of the report; and in the decision to submit the paper for publication. If the funding source(s) had no such involvement then
this should be stated. Please see
http://www.elsevier.com/funding.
Funding body agreements
and policies
Elsevier has established agreements and developed policies to allow authors whose articles appear in journals
published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To
learn more about existing agreements and policies please visit
http://www.elsevier.com/fundingbodies.
Open access
This journal offers you the option of making your article freely available to all via the ScienceDirect
platform. To prevent any conflict of interest, you can only make this choice after receiving notification that your article has been
accepted for publication. The fee of $3,000 excludes taxes and other potential author fees such as color charges. In some cases, institutions
and funding bodies have entered into agreement with Elsevier to meet these fees on behalf of their authors. Details of these agreements
are available at
http://www.elsevier.com/fundingbodies. Authors of accepted articles, who wish to take advantage of this
option, should complete and submit the order form (available at
http://www.elsevier.com/locate/openaccessform.pdf). Whatever
access option you choose, you retain many rights as an author, including the right to post a revised personal version of your article
on your own website. More information can be found here:
http://www.elsevier.com/authorsrights.
Language
Services
Authors who require information about language editing and copyediting services pre- and post-submission please
visit
http://www.elsevier.com/languagepolishing or our customer support site at
http://epsupport.elsevier.com
for more information. Please write your text in good English (American or British usage is accepted, but not a mixture of these).
Please
note Elsevier neither endorses nor takes responsibility for any products, goods or services offered by outside vendors through our services
or in any advertising. For more information please refer to our Terms & Conditions:
http://www.elsevier.com/termsandconditions
Submission
Submission to this journal proceeds totally online. Use the following guidelines to prepare your
article. Via the homepage of this journal (
http://www.elsevier.com/journals) you will be guided stepwise through the creation
and uploading of the various files. The system automatically converts source files to a single Adobe Acrobat PDF version of the article,
which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF at submission for
the review process, these source files are needed for further processing after acceptance. All correspondence, including notification
of the Editor's decision and requests for revision, takes place by e-mail and via the author's homepage, removing the need for a hard-copy
paper trail.
It is a condition of publication that all manuscripts must be written in clear, grammatical English and be submitted
to the
Gynecologic Oncology Web site at
http://ees.elsevier.com/ygyno. Authors are requested to transmit the text
and art of the manuscript in electronic form to this address. Each manuscript must also be accompanied by a cover letter. (Please see
Preparation of Manuscript below.) If you are unable to provide an electronic version, please contact the editorial office prior to submission
by e-mail (
gyn@elsevier.com), telephone +1 619 699 6767, or fax +1 (619) 699 6211.
Manuscripts are accepted for review
with the understanding that no substantial portion of the study has been published or is under consideration for publication elsewhere
and that its submission for publication has been approved by all of the authors and by the institution where the work was carried out.
Authors must disclose prior presentation at a public scientific meeting as a footnote on the title page.
Manuscripts that do not meet
the general criteria or standards for publication in
Gynecologic Oncology will be immediately returned to the authors, without
detailed review.
Please follow this link for a detailed list of the
submission requirements and how to structure your article:
Check
List for Authors
Essential title page information
Please follow this link for
a detailed list of the submission requirements and how to structure your article:
Check
List for Authors
•
Title.
Concise and informative. Titles are often used in information-retrieval
systems. Avoid abbreviations and formulae where possible.
•
Author names and affiliations.
Where the family name
may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work
was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in
front of the appropriate address. Provide the full postal address of each affiliation, including the country name, and, if available,
the e-mail address of each author.
•
Corresponding author.
Clearly indicate who will handle correspondence at
all stages of refereeing and publication, also post-publication.
Ensure that telephone and fax numbers (with country and area code)
are provided in addition to the e-mail address and the complete postal address.
•
Present/permanent address.
If an author has moved since the work described in the article was done, or was visiting at the time, a "Present address" (or "Permanent
address") may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained
as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Graphical abstract
A
Graphical abstract is optional and should summarize the contents of the article in a concise, pictorial form designed to capture the
attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical
abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum
of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular
screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See
http://www.elsevier.com/graphicalabstracts
for examples.
Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images
also in accordance with all technical requirements:
Illustration
Service.
Research highlights
Research highlights are mandatory for this journal.
They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate
file in the online submission system. Please use 'Research highlights' in the file name and include 2 to 3 bullet points (maximum 20
words per bullet point). See
http://www.elsevier.com/researchhighlights for examples.
Database
linking
Elsevier aims at connecting online articles with external databases which are useful in their respective research
communities. If your article contains relevant unique identifiers or accession numbers (bioinformatics) linking to information on entities
(genes, proteins, diseases, etc.) or structures deposited in public databases, then please indicate those entities according to the standard
explained below.
Authors should explicitly mention the
database abbreviation (as mentioned below) together with the actual database
number, bearing in mind that an error in a letter or number can result in a dead link in the online version of the article.
Please
use the following format:
Database ID: xxxx
Links can be provided in your online article to the following databases (examples
of citations are given in parentheses):
•
ASTM: ASTM Standards Database
(ASTM ID: G63)
•
CCDC: Cambridge Crystallographic Data Centre
(CCDC ID: AI631510)
•
GenBank: Genetic sequence database
at the National Center for Biotechnology Information (NCBI) (GenBank ID: BA123456)
•
GEO:
Gene Expression Omnibus (GEO ID: GSE27196; GEO ID: GPL5366; GEO ID: GSM9853)
•
MI:
EMBL-EBI OLS Molecular Interaction Ontology (MI ID: 0218)
•
MINT:
Molecular INTeractions database (MINT ID: 6166710)
•
NCBI Taxonomy:
NCBI Taxonomy Browser (NCBI Taxonomy ID: 48184)
•
NCT: ClinicalTrials.gov
(NCT ID: NCT00222573)
•
OMIM: Online Mendelian Inheritance
in Man (OMIM ID: 601240)
•
PDB: Worldwide Protein Data
Bank (PDB ID: 1TUP)
•
TAIR: The Arabidopsis Information Resource
database (TAIR ID: AT1G01020)
•
UniProt: Universal Protein Resource
Knowledgebase (UniProt ID: Q9H0H5)
Electronic artwork
Please follow this link for a detailed
list of the submission requirements and how to structure your article:
Check
List for Authors
•
Title.
Concise and informative. Titles are often used in information-retrieval
systems. Avoid abbreviations and formulae where possible.
•
Author names and affiliations.
Where the family name
may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work
was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in
front of the appropriate address. Provide the full postal address of each affiliation, including the country name, and, if available,
the e-mail address of each author.
•
Corresponding author.
Clearly indicate who will handle correspondence at
all stages of refereeing and publication, also post-publication.
Ensure that telephone and fax numbers (with country and area code)
are provided in addition to the e-mail address and the complete postal address.
•
Present/permanent address.
If an author has moved since the work described in the article was done, or was visiting at the time, a "Present address" (or "Permanent
address") may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained
as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
General points
• Make
sure you use uniform lettering and sizing of your original artwork.
• Save text in illustrations as "graphics" or enclose the
font.
• Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.
• Number the illustrations
according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions
to illustrations separately.
• Produce images near to the desired size of the printed version.
• Submit each figure
as a separate file.
A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless
of the application used, when your electronic artwork is finalised, please "save as" or convert the images to one of the following formats
(note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS: Vector drawings.
Embed the font or save the text as "graphics".
TIFF: color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF: Combinations bitmapped line/half-tone (color or grayscale): a
minimum of 500 dpi is required.
DOC, XLS or PPT: If your electronic artwork is created in any of these Microsoft Office applications
please supply "as is".
Please do not:
• Supply embedded graphics in your wordprocessor (spreadsheet, presentation)
document;
• Supply files that are optimised for screen use (like GIF, BMP, PICT, WPG); the resolution is too low;
•
Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Submission Checklist
Please follow this link for a detailed list of the submission requirements and how to
structure your article:
Check List for Authors
It is hoped that this list will be useful during the final checking of an article prior to sending it to the journal's Editor for
review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One Author designated as corresponding Author:
• E-mail address
• Full postal address
• Telephone and
fax numbers
All necessary files have been uploaded
• Keywords
• All figure captions
• All tables (including
title, description, footnotes)
Further considerations
• Manuscript has been "spellchecked" and "grammar-checked"
•
References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text,
and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
•
Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print or to be reproduced
in color on the Web (free of charge) and in black-and-white in print
• If only color on the Web is required, black and white
versions of the figures are also supplied for printing purposes
For any further information please visit our customer support site
at
http://epsupport.elsevier.com..
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic
documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial
electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles
in press' because they have not yet received their full bibliographic information. The correct format for citing a DOI is shown as follows
(example taken from a document in the journal
Physics Letters B):
doi:10.1016/j.physletb.2010.09.059
When you use the
DOI to create URL hyperlinks to documents on the web, the DOIs are guaranteed never to change.
Proofs
One
set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper
proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now
provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available
free from
http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany the proofs (also given online).
The exact system requirements are given at the Adobe site:
http://www.adobe.com/products/reader/tech-specs.html.
If
you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them
to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections
and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail,
or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures.
Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor.
We will do everything possible to get your article published quickly and accurately – please let us have all your corrections within
48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying,
as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed
with the publication of your article if no response is received.
For inquiries
relating to the submission of articles (including electronic submission) please visit this journal's homepage. Contact details for questions
arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted
articles at
http://www.elsevier.com/trackarticle. You can also check our Author FAQs (
http://www.elsevier.com/authorFAQ)
and/or contact Customer Support via
http://support.elsevier.com.
